After treatment with white button mushroom extract in mice and patients with prostate cancer, scientists discovered a decline ...

Researchers have identified a new role for the enzyme EZH2 in promoting the progression of aggressive, treatment-resistant ...

Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP ...

No man wants to hear that he has prostate cancer, but if he is diagnosed he will need to learn about the disease and how it ...

We’re finding that plant-derived substances may one day be used to support traditional cancer treatment and prevention ...

In prostate cancer, patients with five or more CTCs at treatment start had significantly shorter median survival compared to those with no detectable CTCs. CTC count can guide clinical trial ...

Prostate cancer is one of the most common cancers in men, and while many cases grow slowly and remain manageable, others can be aggressive and life-threatening. Over the years, treatments like surgery ...

Rupert Crowfoot, 57, was diagnosed with prostate cancer last year after a conversation with a friend encouraged him to get a ...

The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, ...

there are cases of aggressive prostate cancers. The cancer cells may metastasize (spread) from the prostate to other parts of the body, particularly the bones and lymph nodes. Prostate cancer may ...